G001 Gel for Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new topical gel, G001, for individuals with osteoarthritis (OA) of the knee to determine if it can reduce pain and improve safety compared to a placebo gel. Participants will discontinue their usual pain medications to evaluate the gel's effectiveness on its own. This trial may suit those who have experienced mild to moderate knee OA for at least six months and currently endure significant daily knee pain. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing participants an opportunity to contribute to important advancements in OA treatment.
Do I have to stop taking my current medications for the trial?
Yes, you will need to stop taking NSAIDs and acetaminophen before starting the trial to allow for a washout period (time without taking certain medications) and to assess your pain levels without them.
Is there any evidence suggesting that G001 Topical Gel is likely to be safe for humans?
Research has shown that treatments like G001 gel applied to the skin are generally safe. However, caution is advised. Some individuals have reported skin reactions, such as redness or itching, when using topical gels. Serious reactions are rare but possible, so monitoring for any changes is crucial. In this study, the gel is applied to the knee, which may reduce the risk of side effects compared to oral medication. Report any unusual symptoms to the study team immediately.12345
Why do researchers think this study treatment might be promising?
Unlike the standard treatments for osteoarthritis of the knee, which often include oral medications like NSAIDs or injectable options such as corticosteroids and hyaluronic acid, G001 Topical Gel offers a unique approach. This treatment is applied directly to the skin over the affected knee, potentially minimizing systemic side effects associated with oral medications. Researchers are excited about G001 because it promises targeted relief while maintaining a convenient and non-invasive application method. Additionally, the topical nature of G001 may allow for more frequent dosing, which could enhance its effectiveness in managing pain and inflammation associated with osteoarthritis.
What evidence suggests that G001 Topical Gel might be an effective treatment for OA of the knee?
Studies have shown that topical diclofenac products, such as G001 Topical Gel, significantly aid individuals with knee osteoarthritis by reducing pain and enhancing movement compared to a placebo. Earlier research found that participants using diclofenac gel experienced less knee pain and improved mobility. These improvements were measured using the WOMAC pain index, a standard method for assessing pain levels and movement ease. Additionally, diclofenac gels are generally safe and well-tolerated over several weeks of use. These findings suggest that G001 Topical Gel, which participants in this trial may receive, could effectively reduce knee pain and assist with daily activities for those with osteoarthritis.678910
Who Is on the Research Team?
Deirdre O'Keeffe, PhD
Principal Investigator
Buzzz Pharma
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive G001 or Vehicle topical gel applied to the index knee four times a day
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- G001 Topical Gel
- Vehicle
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
G001 Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
Vehicle Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
BUZZZ Pharmaceuticals Limited
Lead Sponsor
Veristat, Inc.
Collaborator
Citations
Safety and efficacy of topical diclofenac sodium gel for ...
Conclusions: DSG was effective and generally well tolerated in adults regardless of age. These data support the topical application of DSG for relief of OA knee ...
2.
bmcmusculoskeletdisord.biomedcentral.com
bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-025-08465-7Efficacy and safety of different topical diclofenac formulations ...
Topical diclofenac formulations (gel, solution, patch) significantly improve pain and function in knee osteoarthritis compared to placebo.
3.
haleonhealthpartner.com
haleonhealthpartner.com/en-us/pain-relief/brands/voltaren/science/knee-efficacy-clinical-study-data/Clinical Study Data: Knee Efficacy
Results: Patients treated with DSG 1% exhibited significant improvement compared to vehicle in: Mean WOMAC pain index at Week 12; Mean WOMAC physical function at ...
Evaluating the Real-World Use of Topical Diclofenac Sodium ...
In clinical studies, DSG1% was shown to be safe and well-tolerated in patients with hand or knee OA for up to 8 weeks' and 12 weeks' duration, ...
5.
clinicaltrials.eu
clinicaltrials.eu/trial/study-on-the-effectiveness-of-diclofenac-gel-amz001-for-treating-knee-osteoarthritis-pain-in-adults/Study on the Effectiveness of Diclofenac Gel AMZ001 for ...
The purpose of the study is to evaluate how effective and safe the diclofenac gel AMZ001 is in reducing knee pain and symptoms associated with ...
6.
safcodental.com
safcodental.com/media/catalog/SDS/$3350006.pdf?srsltid=AfmBOoon6TB4RyMDWcHhZK5vuYi0Eui_4tY98Tq3FwnlfSfG6eUVAJEFSAFETY DATA SHEET
Precautionary statements. Prevention. : Wear protective gloves. Wear eye or face protection. Wash hands thoroughly after handling. Response.
7.
dailymed.nlm.nih.gov
dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=8aeb1434-6a8a-4ac1-9c9a-b488bd483119&type=pdfGELATO TOPICAL ANESTHETIC
Other Ingredients. Ingredient Kind. Ingredient Name. Quantity. May contain. FD&C YELLOW NO. 5 (UNII: I753WB2F1M). May contain. FD&C YELLOW NO.
ZAP - Safety Data Sheet
Hazard statements (GHS-CA). : H317 - May cause an allergic skin reaction. H319 - Causes serious eye irritation. H370 - Causes damage to organs.
SAFCO SENSICAINE ULTRA TOPICAL ANESTHETIC GEL
Methemoglobinemia warning: Use of this product may cause methemoglobinemia, a serious condition that must be treated promptly because it reduces the amount ...
SAFETY DATA SHEETS This SDS ...
Primary Routes of Exposure. Ingestion: May cause gastrointestinal tract irritation with nausea, vomiting, diarrhea. May affect.
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.